During the past decade, Shizuoka Cancer Center conducted 105 clinical trials. In the 10-year time frame, 105 clinical trials started and 49 clinical trials were completed, i.e. on average, 46.7% percent of trials that started reached the finish line to date. In the past 5 years, 55 clinical trials started and 34 clinical trials were completed. i.e. 61.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Shizuoka Cancer Center" #1 sponsor was "Pfizer" with 20 trials, followed by "Hoffmann-La Roche" with 16 trials sponsored, "Daiichi Sankyo, Inc." with 9 trials sponsored, "Amgen" with 8 trials sponsored and "Janssen Research & Development, LLC" with 8 trials sponsored. Other sponsors include 75 different institutions and companies that sponsored additional 48 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Shizuoka Cancer Center" #1 collaborator was "AstraZeneca" with 7 trials as a collaborator, "Merck Sharp & Dohme LLC" with 5 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 4 trials as a collaborator, "Eli Lilly and Company" with 4 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 4 trials as a collaborator. Other collaborators include 59 different institutions and companies that were collaborators in the rest 56 trials.

According to Clinical.Site data, the most researched conditions in "Shizuoka Cancer Center" are "Carcinoma, Non-Small-Cell Lung" (10 trials), "Breast Cancer" (8 trials), "Colorectal Cancer" (8 trials), "Non-Small Cell Lung Cancer" (7 trials) and "Gastric Cancer" (6 trials). Many other conditions were trialed in "Shizuoka Cancer Center" in a lesser frequency.

Most popular intervention types in "Shizuoka Cancer Center" are "Drug" (133 trials), "Other" (14 trials), "Radiation" (7 trials), "Procedure" (5 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Carboplatin" (17 trials), "Cisplatin" (14 trials), "Atezolizumab" (13 trials) and "Paclitaxel" (13 trials). Other intervention names were less common.

The vast majority of trials in "Shizuoka Cancer Center" are 122 trials for "All" genders and 18 trials for "Female" genders.

Currently, there are NaN active trials in "Shizuoka Cancer Center". undefined are not yet recruiting, 40 are recruiting, 34 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 52 completed trials in Shizuoka Cancer Center, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Shizuoka Cancer Center, 29 "Phase 1" clinical trials were conducted, 41 "Phase 2" clinical trials and 76 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Shizuoka Cancer Center has several departments that took part in Clinical trials: "Sizuoka Cancer Center" - 7 trials, "Shizuoka Cancer Center; Thoracic Oncology" - 4 trials, "Shizuoka Cancer Center Hospital and Research Institute ( Site 0802)" - 4 trials, "Shizuoka Cancer Center; Breast Surgery" - 2 trials, "Shizuoka Cancer Center; Female Internal Medicine" - 2 trials, "Shizuoka Cancer Center; Urology" - 2 trials